Angle Takeover Rumours (AGL)

Buy
Sell

Angle Chart

Angle Takeover Price

Angle Takeover Forum Posts

29-04-2020
Once FDA approval is granted, it is game on. Logic says that AGL will want to partner with Abbott and then to replicate the same as other indications come on stream, however it is possible they don't get that opportunity at all and that an early bid is just made for the company. It is really one of the attractions about Angle. There are a succession of steps that will occur in the next year, all of which are inflection points and each one could transform the share price. Q2 - Lockdown lifted and small number of residual samples now collectable Q2/Q3 - FDA application Q3 - ovarian results Q4 - FDA approval Q1 - Licensing / Partnership Deals / Takeover Bid
Thanks both - I thought my memory of base costs and multiples was muddled. Given this potential and the evidence base available I just don’t get why a mega cash rich pharma hasn’t looked to build a major stake then launched a hostile takeover before now or soon as IMHO they would likely get it at c 1.50 - £2 whereas on FDA approval and/or major adoption that just wouldn’t cut the mustard. Is that the line of thinking of others ?
28-04-2020
Add to that I don’t expect a takeover either! Just a steady growing business
11-02-2020
Yes the breadth of potential ground breaking applications is truly incredible. I agree the FDA remains a critical tipping point and my only real concern here is how close behind any true competitor is - if there is one - as these time delays buy them time. I remember from some years ago ( apart from of course the primary issue of patient benefit) thinking that the income generation potential from Angle is virtually limitless as they charge ‘per test’ - so the more different applications that get adopted multiply the cassette sales over time. My biggest fear remains that until we get to do day’ we are at risk of a takeover from a major pharma. Time will tell
01-02-2020
Interesting that the interims RNS refers to the prospect of FDA approval in Q3 then, in his presentation later in the day, Newland states the end of Q3. His usual timing banana slide has started. I also appreciated those analyst questions at the end. Profit visibility, if they get FDA approval, is muddy to say the least. I can see how this needs takeover chat to support a market cap over £120 million.
ADVFN Advertorial
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200528 21:54:34